|
MechanismErgosterol modulators |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1958 |
/ Not yet recruitingPhase 3 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).
Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acid to ENHANCE Efficacy in Adults With Hypertriglyceridemia: The ENHANCE-IT Trial
Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia
A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
100 Clinical Results associated with Matinas BioPharma Nanotechnologies, Inc.
0 Patents (Medical) associated with Matinas BioPharma Nanotechnologies, Inc.
100 Deals associated with Matinas BioPharma Nanotechnologies, Inc.
100 Translational Medicine associated with Matinas BioPharma Nanotechnologies, Inc.